Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4152W HIGH $3.43
Volume
65.08 K
Value Traded
394.45 K
Short % Float
15.07%
+3.14%Week
-1.99%1 Month
-17.57%3 Month
-13.22%6 Month
-99.9%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
125.54 M
EPS (TTM)
-0.48
P/E Ratio
-
Ent. Value
128.15 M
Total Shares
63.66 M
Float Shares
41.66 M
Insiders
34.62%
Institutions
14.28%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
HURA Catalyst Timeline
Dated clinical, regulatory and corporate events for TuHURA Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for TuHURA Biosciences, Inc.
395Total events
30Upcoming
65Tier-1 (high impact)
2014 to 2043Coverage
Upcoming catalysts 2
Event history 50
▲Patent GrantedIP / Competition
USPTO issued U.S. Patent No. 12,734,168 for DOR antagonist technology
cancersource ↗
▲IND ClearanceTBS-2025IND
FDA clears IND for TBS-2025 VISTA-inhibiting antibody in AML and other blood-related cancers
molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood-related cancerssource ↗
▲Trial InitiationTBS-2025Trial
Phase 1b study of TBS-2025 in r/r mutNPM1 AML allowed to proceed
relapsed/refractory (r/r) mutNPM1 AMLsource ↗
▲FDA Feedback ReceivedTBS-2025FDA Meeting
FDA provided written responses to questions on TBS-2025 development plan
AMLsource ↗
▲Trial InitiationTBS-2025Trial
Initiate Phase 1b/2 trial of VISTA in mut NPM1 r/r AML
mut NPM1 r/r AMLsource ↗
●IND SubmissionTBS-2025IND
Filed IND for TBS-2025 VISTA inhibiting antibody
Acute Myeloid Leukemia (AML) and other blood related cancerssource ↗
◆FDA Feedback ReceivedTBS-2025FDA Meeting
FDA provided written feedback and guidance on development plan for TBS-2025
Acute Myeloid Leukemia (AML)source ↗
◆Oral PresentationPresentation
TuHURA Biosciences to present at 4th Annual H.C. Wainwright BioConnect Investor Conference
▲Orphan Drug DesignationIFx-2.0Designation
FDA Orphan Drug Designation for IFx-2.0 in cutaneous melanoma
cutaneous melanoma (stage IIB to stage IV)source ↗
▲Debt Royalty FinancingCorporate
Entered into $50 million credit facility and royalty agreement with K&V Investment One LLC
▲Debt Royalty FinancingCorporate
Announced $50 million credit facility and royalty transaction
◆Oral PresentationPresentation
Data on inhibiting DOR on MDSCs, TAMs and T regs at a scientific conference in 2Q
cancer (general)source ↗
▲Management ChangeCorporate
Dr. Craig Tendler to provide CMO services for TuHURA, overseeing TBS-2025 program
▲FDA Feedback ReceivedTBS-2025FDA Meeting
Preliminary FDA feedback received on TBS-2025 early development plan
NPM1-mutated AML and other blood-related cancerssource ↗
◆Oral PresentationPresentation
Presentation at Oppenheimer 36th Annual Healthcare Life Sciences Conference
▲Trial InitiationIFx-2.0Trial
Initiated Phase 3 registration trial of IFx-2.0 in first-line Merkel Cell Carcinoma
advanced or metastatic Merkel Cell Carcinomasource ↗
▲Orphan Drug DesignationIFx-2.0Designation
FDA granted Orphan Drug Designation for IFx-2.0 for cutaneous melanoma
Stage IIB to Stage IV cutaneous melanomasource ↗
●Trial InitiationTBS-2025Trial
Initiation of Phase 2 randomized study of TBS-2025
NPM1 mutated AMLsource ↗
◆Orphan Drug DesignationIFx-2.0Designation
Anticipate Orphan Drug Designation for IFx-2.0 in MCC
Merkel Cell Carcinoma (MCC)source ↗
◆IND SubmissionTBS-2025IND
Planned FDA IND meeting regarding Phase 1b/2 development plan
mutNPM1 r/r AMLsource ↗
◆Development Candidate NominationPreclinical
Select lead ADC for proof-of-concept study in AML
AMLsource ↗
◆Topline ReadoutIFx-2.0Clinical Data
Anticipated topline results from Phase 1b/2a trial in MCCUP
MCC of unknown primary origin (MCCUP)source ↗
◆Enrollment MilestoneREM-001Trial
Enrollment of 10 cutaneous metastatic breast cancer patients expected to complete by December 31, 2025
cutaneous metastatic breast cancersource ↗
▲Primary Endpoint MetREM-001Clinical Data
REM-001 meets primary safety endpoint with signs of clinical efficacy in metastatic cutaneous breast cancer trial
metastatic cutaneous breast cancersource ↗
▲Milestone PaymentCorporate
CVR milestone achieved triggering release of 1,539,958 shares to legacy Kintara stockholders
▲SPA AgreementIFx-2.0FDA Meeting
SPA agreement with FDA for Phase 3 trial of IFx-2.0 as adjunctive therapy with Keytruda in first-line MCC
advanced and metastatic Merkel cell carcinomasource ↗
●Oral PresentationPresentation
Oral and poster presentations at 57th ASH Annual Meeting showing DOR as new target for bi-functional bi-specific immune modulating ADCs
cancer (general)source ↗
●Quarterly UpdateCorporate
Management conference call to discuss corporate update and recent financing
▼Equity OfferingCorporate
Announced $15.6 million registered direct offering of common stock and warrants
●Oral PresentationPresentation
Oral presentation on DOR expression on MDSCs as a novel target to overcome ICI resistance
Cancer (immunotherapy resistance)source ↗
◆Poster PresentationPresentation
Poster presentation on DOR expressing MDSCs in MDS patients at ASH 2025
Myelodysplastic Syndromes (MDS)source ↗
Past FDA Catalysts and PDUFA Decisions
How HURA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | KVA12123 | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D33 / 100
Pipeline Score
$8M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.1x
rNPV / MCap
Top 60%
Micro Cap(rank 395 of 658)
Percentile Rank
TuHURA Biosciences, Inc. faces pipeline headwinds (33/100), with $515M risk-adjusted pipeline value, led by IFx-Hu2.0 in Cutaneous Squamous Cell Carcinoma (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IFx-Hu2.0 Small moleculeNCT06940440 | Advanced Or Metastatic Merkel Cell Carcinoma | Phase 2 | RECRUITING | 127 | May 31, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every HURA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| REM-001 | metastatic cutaneous breast cancer | Phase 3 | 2025-12-15 | ten metastatic cutaneous breast cancer patients met its primary endpoint demonstrating safety with signs of clinical efficacy following eight weeks of follow-upRead More | TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual MilestoneRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bianco James A.Director, Officer (Chief Executive Officer) | Disposition | -150,000 2,173,307 held | $0.00 | 05/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HURA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in HURA for Q2 2026. | ||||
HURA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HURA ranks across every disease it competes in
Competitive Position is a premium feature
See how HURA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHURA News
HURATuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
TuHURA Biosciences has been granted U.S. Patent No. 12,734,168 for its Delta Opioid Receptor (DOR) technology, which aims to enhance cancer immunotherapy effectiveness. The patent allows for various applications, including adoptive cellular immunotherapies. The company is focused on overcoming resistance to cancer treatments and is advancing its bi-functional ADCs in clinical trials.
Read more →HURATuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
TuHURA Biosciences has received FDA clearance for its Investigational New Drug application for TBS-2025, a VISTA-inhibiting antibody aimed at treating molecularly defined subsets of Acute Myeloid Leukemia (AML). The FDA's 'Study May Proceed' notice enables the company to conduct a Phase 1b study focusing on patients with relapsed/refractory mutNPM1 AML. This study aims to evaluate the safety and efficacy of TBS-2025, which has shown promising results in preclinical models.
Read more →HURATuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
TuHURA Biosciences, Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. CEO James A. Bianco will discuss the company's Phase 3 immuno-oncology therapies aimed at overcoming resistance to cancer immunotherapy. The lead candidate, IFx-2.0, is currently in a registration trial for advanced Merkel Cell Carcinoma.
Read more →HURA▲ +7.4%on this news
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences reported its second quarter 2026 financial results, highlighting significant advancements in its clinical programs. The company anticipates receiving FDA feedback and initiating several trials in the second half of the year. A $50 million credit facility has been secured to support ongoing operations. However, the company faces increased cash outflows and risks related to its clinical trials.
Read more →HURATuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
TuHURA Biosciences, Inc. will present at Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026. CEO Dr. James A. Bianco will discuss the company's Phase 3 immuno-oncology developments, including the trial of IFx-2.0. TuHURA is also advancing TBS-2025 in a Phase 1b trial for AML. The company focuses on overcoming resistance in cancer therapies.
Read more →HURATuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
TuHURA Biosciences has filed an IND application with the FDA for TBS-2025, a VISTA-inhibiting antibody aimed at treating molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood cancers. The FDA has provided guidance on the development plan, allowing TuHURA to combine Phase 1b and Phase 2 studies for efficiency. The company aims to initiate the trial in late 2026, addressing significant unmet medical needs in AML and high-risk myelodysplasia patients.
Read more →HURA▼ -8%on this news
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences reported its Q1 2026 financial results, highlighting a $50 million credit facility to support operations. The company anticipates key milestones, including FDA discussions for its VISTA inhibitor and the initiation of a Phase 1b/2 trial for TBS-2025. Additionally, TuHURA received FDA Orphan Drug Designation for IFx-2.0 in melanoma.
Read more →HURATuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
TuHURA Biosciences, Inc. will present at the 4th Annual H.C. Wainwright BioConnect Investor Conference on May 19, 2026. CEO James A. Bianco will participate in a fireside chat, discussing the company's Phase 3 immuno-oncology developments. TuHURA is focused on overcoming resistance to cancer therapies with its lead product, IFx-2.0, and other innovative candidates.
Read more →HURA▲ +6.7%on this news
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Unless the context indicates otherwise in this Unaudited Pro Forma Condensed Combined Financial Information, references to "TuHURA," "TuHURA Biosciences, Inc."
TuHURA Biosciences, Inc. has successfully completed its merger with Kineta, enhancing its capabilities and expanding its portfolio. The mergers were treated as a business combination under U.S. GAAP, with TuHURA identified as the accounting acquirer. Following the merger, TuHURA plans to advance the clinical development of Kineta's trials and explore synergies with its ongoing studies. The financial information presented reflects the combined operations and anticipated future developments post-merger.
Read more →HURATuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
TuHURA Biosciences has announced a $50 million credit facility to fund its clinical pipeline, including the Phase 3 trial of IFx-2.0. The agreement allows the company to draw funds as needed, with a 12% interest rate and a five-year maturity. This funding is expected to support operations through key milestones, including anticipated Phase 3 results. The company also granted a royalty on sales of products based on IFx-2.0 to the lender.
Read more →HURATuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
TuHURA Biosciences has appointed Amanda Garofalo as Senior Vice President of Clinical Operations. With over 20 years of experience in drug development, she will oversee daily clinical operations and collaborate with the executive team. Her expertise is anticipated to strengthen TuHURA's clinical programs, including the Phase 3 trial of IFx-2.0.
Read more →HURA▼ -9.5%on this news· ran to -21% by day 1shared move
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
TuHURA Biosciences reported its financial results for Q4 and the full year of 2025, highlighting strong progress in its clinical development pipeline. The company has initiated a Phase 3 trial for its lead candidate, IFx-2.0, and made advancements in its VISTA inhibiting antibody program. Financially, TuHURA raised $21.2 million but also faced increased operating expenses.
Read more →HURACraig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
TuHURA Biosciences has appointed Dr. Craig Tendler as the leader of its VISTA program targeting acute myeloid leukemia (AML) and other blood cancers. Dr. Tendler, with over 29 years of experience in oncology, will oversee clinical development strategies for the company's TBS-2025 antibody. His previous successes in drug approvals are expected to enhance TuHURA's regulatory pathways.
Read more →HURATuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
TuHURA Biosciences has confirmed compliance with Nasdaq's minimum bid price requirement, with its stock closing above $1.00 for 11 consecutive business days. The company is focused on advancing its clinical trials, including a Phase 3 trial for IFX-2.0 in Merkel Cell Carcinoma and preparing for a Phase 2 study of TBS-2025 in relapsed/refractory AML.
Read more →HURA▲ +20%on this newsshared move
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences
TuHURA Biosciences, Inc. announced its participation in two upcoming investor conferences, the Citizens Life Science Conference and the Leerink Global Healthcare Conference. Dr. James Bianco, the CEO, will represent the company at these events. TuHURA is focused on developing innovative therapies to combat resistance to cancer immunotherapy, particularly through its lead product, IFx-2.0.
Read more →HURA▼ -15%on this news
TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
TuHURA Biosciences has submitted an IND to the FDA for TBS-2025, aimed at treating mut NPM1 relapsed/refractory AML in combination with a menin inhibitor. The company plans to initiate a Phase 2 study in early Q2 2026, targeting improved response rates and duration of treatment. TBS-2025 is a VISTA inhibiting antibody with a favorable safety profile from prior trials.
Read more →HURA▲ +7.8%on this newsshared move
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
TuHURA Biosciences, Inc. will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The company focuses on developing novel immuno-oncology therapeutics to combat resistance to cancer treatments. Their lead product, IFx-2.0, is currently in a Phase 3 trial for advanced Merkel Cell Carcinoma. Additionally, TuHURA has expanded its pipeline through a merger with Kineta Inc.
Read more →HURATuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
TuHURA Biosciences has received FDA Orphan Drug Designation for its drug IFx-2.0, aimed at treating stage IIB to IV cutaneous melanoma. This designation is based on positive results from a Phase 1 study, which indicated safety and potential benefits for patients resistant to existing therapies. The company is now focusing on completing enrollment for a Phase 3 study combining IFx-2.0 with Keytruda for advanced Merkel Cell Carcinoma.
Read more →HURA▼ -6%on this news
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
TuHURA Biosciences announced that Kintara's REM-001 clinical trial met its primary safety endpoint, showing signs of clinical efficacy in patients with metastatic cutaneous breast cancer. This achievement triggers the release of 1,539,958 shares of TuHURA common stock to legacy Kintara stockholders, expected within ten business days. TuHURA continues to develop novel immuno-oncology therapies.
Read more →About TuHURA Biosciences, Inc.
Headquarters10500 UNIVERSITY CENTER DR., TAMPA, FL, 33612
BIOPHARMAWATCH ELITE PLUS
Trade the next HURA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime